Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clearmind Medicine Inc CMND

Healthcare
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or... see more

Recent & Breaking News (NDAQ:CMND)

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

GlobeNewswire October 10, 2024

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

GlobeNewswire September 16, 2024

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment

GlobeNewswire September 12, 2024

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

GlobeNewswire September 6, 2024

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

GlobeNewswire September 6, 2024

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment

GlobeNewswire August 29, 2024

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

GlobeNewswire August 21, 2024

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

GlobeNewswire August 16, 2024

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug

GlobeNewswire August 6, 2024

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

GlobeNewswire August 6, 2024

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine - Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research

GlobeNewswire July 31, 2024

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

GlobeNewswire July 19, 2024

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

GlobeNewswire July 16, 2024

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

GlobeNewswire July 16, 2024

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

GlobeNewswire July 16, 2024

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine - Israel 2024 Conference

GlobeNewswire July 12, 2024

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

GlobeNewswire June 28, 2024

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

GlobeNewswire June 20, 2024

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

GlobeNewswire June 11, 2024

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

GlobeNewswire May 10, 2024